Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Estimates Investment in Verinata at $3.1M After Illumina Acquisition

NEW YORK (GenomeWeb News) – Fluidigm disclosed in its Form 10-K this week that the fair value of its investment in Verinata Health is an estimated $3.1 million.

In its document filed with the US Securities and Exchange Commission, the South San Francisco, Calif.-based firm said it is a minority equity investor in Verinata, which was recently acquired by Illumina for $450 million. The carrying value — a measurement of an asset based on the company's balance sheet — of the investment, it added, was $1.3 million as of Dec. 31, 2012.

Under the terms of Illumina's acquisition of Verinata, it paid $350 million in cash. Based on that figure, Fluidigm estimated the fair value of its investment at $3.1 million as of Dec. 31, 2012.

Verinata is also eligible to receive milestone payments from Illumina of up to $100 million through 2015. Fluidigm said it did not factor these milestones into its fair value estimates because it is unable to assess the probability of such payments or when they would be made.

As a result, Fluidigm made a fair value estimate on its investment using Level 2 inputs, a method of evaluating a company's assets based on the degree of certainty around the asset's underlying value.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.